Hormonal
Unimolecular GIPR:GLP-1R coagonists (e.g., tirzepatide) achieve superior body weight loss compared to GLP-1R monoagonists (e.g., semaglutide) in both diabetic and non-diabetic obese populations, with efficacy scaling with dose without compromising tolerability.
If you are treating obesity with medication, combining GIP and GLP-1 receptor activation (like tirzepatide) yields significantly more weight loss than activating only the GLP-1 receptor (like semaglutide). This combination does not increase the side effects that typically limit treatment, allowing for higher effective doses.
Collectively, these data demonstrate that tirzepatide outperforms semaglutide in body weight endpoints without compromising its tolerability.
Why this rating
Supported by multiple phase III clinical trials (SURPASS, SURMOUNT) and large real-world data (n>41,000).
Source
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff et al. · Physiology · 2024
DOI 10.1152/physiol.00032.2023
More from this paper
- GIPR agonism mitigates the gastrointestinal adverse effects (nausea/vomiting) associated with GLP-1R agonism, thereby allowing for higher maximal tolerated doses of GLP-1-based therapies.Good
- GIPR signaling in the central nervous system (specifically GABAergic neurons) is required for the body weight-lowering effects of GIP-based therapies, whereas peripheral GIPR signaling in adipose tissue has complex, context-dependent effects on lipolysis vs lipogenesis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →